Q2 clinical trials round-up: April to June 2025
The second quarter of 2025 has seen a surge of clinical trial activity across the pharmaceutical and biotech landscape.
European Commission approves 2nd IPCEI to sum of €403m
The European Commission has approved, under EU State aid rules, the second health-related IPCEI to support innovations in medical devices.
AI health tech Respiree closes $11.6m Series A
Health tech Respiree, developer of AI platforms to manage disease progression, has announced the successful closing of an $11.6m Series A financing.
Replimune receives CRL on BLA for RP1 for advanced melanoma
Replimune has announced the FDA has issued a Complete Response Letter regarding the Biologics License Application for RP1 combined with nivolumab.
Featured Content
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
2nd Hit ID Summit
Why prioritise your hit discovery game? Finding the right chemical start points is crucial to help you save time and costs in the long run.
Unlocking the Potential of Targeting the Innate Immune Syste...
Ready to Catalyze the Next Wave of Inflammasome Therapies?
The Inaugural Market Access for CNS Therapeutics Summit Has ...
The only dedicated forum focused on tackling the unique commercial and reimbursement challenges facing treatments for neurodegeneration...
5th Oligonucleotides for CNS Summit
The Oligonucleotides for CNS Summit returns for its 5th year to address key challenges in durability, scalability, potency and CNS tropism
Immune Cell Engager Partnering & Investment Summit
Driving high ROI across immune cell engagers through strategic partnerships & investments, capitalizing on novel targets & asset tunability...